TEST BANK FOR CLAYTON’S BASIC PHARMACOLOGY FOR
NURSES 19TH EDITIONBY MICHELLE J. WILLIHNGANZ,
SAMUEL L. GUREVITZ, BRUCE CLAYTON COMPLETE
,Chapter 8t01: 8tDrug 8tDefinitions, 8tStandards, 8tand 8tInformation 8tSources
8tWillihnganz: 8tClayton’s 8tBasic 8tPharmacology 8t for 8tNurses, 8t19th 8tEdition
MULTIPLE
8tCHOICE
1. Which 8tname 8tidentifies 8ta 8tdrug 8tlisted 8tby 8tthe 8tUS
8t Food 8tand8tDrug 8tAdministration 8t(FDA)?
a. Brand
b. Nonproprietary
c. Official
d. Trademark
ANS: 8t C
The 8tofficial 8tname 8tis 8tthe 8 t name 8tunder 8twhich 8ta 8tdrug 8tis
8tlisted 8tby 8tthe 8tFDA. 8tThe 8tbrand 8tname, 8tor 8ttrademark, 8tis
8tthe 8tname 8tgiven 8tto 8ta 8tdrug 8tby 8tits 8tmanufacturer. 8tThe
8tnonproprietary, 8tor 8tgeneric, 8tname 8tis 8tprovided 8tby 8tthe
8tUnited 8tStates 8tAdopted 8tNames 8tCouncil.
DIF: Cognitive 8tLevel: 8tKnowledge REF: 8 t p. 8t9
OBJ: 8t1NAT: 8tNCLEX 8tClient 8tNeeds 8tCategory: 8tSafe,
8tEffective 8tCare8E
t nvironment 8tTOP: 8 t Nursing 8tProcess 8tStep:
8tAssessment CON:
8tPatient 8tEducation
2. Which 8tsource 8tcontains 8tinformation 8tspecific 8tto 8tnutritional 8tsupplements?
a. USP 8tDictionary 8tof 8tUSAN 8t &8tInternational 8tDrug 8tNames
b. Natural 8tMedicines 8tComprehensive 8tDatabase
c. United 8tStates 8tPharmacopoeia/National 8tFormulary 8t(USP 8tNF)
d. Drug 8tInteraction 8tFacts
ANS: 8t C
United 8tStates 8tPharmacopoeia/National 8tFormulary 8tcontains 8tinformation 8tspecific 8tto
8tnutritional8s t upplements. 8tUSP 8tDictionary 8tof 8tUSAN 8t& 8tInternational 8tDrug 8tNames 8tis 8ta
8tcompilation 8tof 8tdrug8tnames, 8tpronunciation 8tguide, 8tand 8tpossible 8tfuture 8tFDA 8tapproved
8tdrugs; 8tit 8tdoes 8tnot 8tinclude 8tnutritional 8tsupplements. 8t Natural 8tMedicines 8tComprehensive
8tDatabase 8tcontains
evidence-based 8tinformation 8ton 8therbal 8tmedicines 8tand 8therbal 8tcombination 8tproducts; 8tit
8tdoes 8tnot8tinclude 8tinformation 8tspecific 8tto 8tnutritional 8tsupplements. 8tDrug 8tInteraction
8tFacts 8tcontains 8tcomprehensive 8t information 8ton 8tdrug 8t interaction 8tfacts; 8tit 8t does 8tnot
8t include 8tnutritional 8tsupplements.
DIF: Cognitive 8tLevel: 8tKnowledge REF: 8 t p. 8t4 OBJ:
8t38tNAT: 8 t NCLEX 8tClient 8t Needs 8t Category: 8tPhysiological 8tIntegrity
TOP: 8 t Nursing 8tProcess 8tStep: 8tAssessment CON: 8 t Nutrition 8t| 8tPatient 8t Education
3. Which 8tdrug 8treference 8tcontains 8tdrug 8tmonographs 8tthat 8tdescribe 8tall 8tdrugs 8tin 8ta 8ttherapeutic 8tclass?
a. Drug 8tFacts 8tand 8tComparisons
,Test 8tBank 8tFor 8tClayton’s 8tBasic 8tPharmacology 8tfor 8tNurses 8t19th 3
8tEdition
b. Drug 8tInteraction 8tFacts
c. Handbook 8ton 8tInjectable 8tDrugs
d. Martindale—The 8tComplete 8tDrug 8tReference
ANS: 8 t A
Drug 8tFacts 8tand 8tComparisons 8tcontains 8tdrug 8tmonographs 8tthat 8tdescribe 8tall
8tdrugs 8tin 8ta8ttherapeutic 8tclass. 8tMonographs 8tare 8tformatted 8tas 8ttables 8tto 8tallow
8tcomparison 8tof 8tsimilar8tproducts, 8tbrand 8tnames, 8tmanufacturers, 8tcost 8tindices, 8tand
8tavailable 8tdosage 8tforms 8tOnline 8tversion 8tis 8tavailable.
DIF: Cognitive 8tLevel: 8tKnowledge REF: 8 t p. 8t4 8tTable 8t1.2
OBJ: 8t 8t 8 t 3 NAT: 8 t NCLEX 8tClient 8tNeeds 8tCategory: 8tPhysiological 8tIntegrity
TOP: 8 t Nursing 8tProcess 8tStep: 8tAssessment CON: 8 t Safety 8t| 8tPatient 8tEducation 8t| 8tClinical 8tJudgment
4. Which 8tdrug 8treference 8tcontains 8t monographs 8tabout 8t virtually 8tevery8tsingle-entity8tdrug
available8tin 8tthe 8tUnited 8tStates 8tand 8tdescribes 8ttherapeutic 8tuses 8tof 8tdrugs, 8tincluding
8t
approved 8tand 8tunapproved 8tuses?
8t
a. Martindale: 8tThe 8tComplete 8tDrug 8tReference
b. AHFS 8tDrug 8tInformation
c. Drug 8tReference
d. Drug 8tFacts 8tand 8tComparisons
ANS: 8 t B
AHFS 8tDrug 8tInformation 8tcontains 8tmonographs 8tabout 8tvirtually 8tevery 8tsingle-entity 8tdrug
8tavailable 8tin 8tthe 8tUnited 8tStates 8tand 8tdescribes 8ttherapeutic 8tuses 8tof 8tdrugs, 8t including
8tapproved 8tand8tunapproved 8t uses.
DIF: Cognitive 8tLevel: 8tKnowledge REF: 8 t p. 8t4 8tTable 8t1.2
OBJ: 8t 8t 8 t 3 NAT: 8 t NCLEX 8tClient 8tNeeds 8tCategory: 8tPhysiological 8tIntegrity
TOP: 8 t Nursing 8tProcess 8tStep: 8tPlanning CON: 8 t Safety 8t| 8tPatient 8tEducation 8t| 8tClinical 8tJudgment
5. Which 8tonline 8tdrug 8treference 8tmakes 8tavailable 8tto 8thealthcare 8tproviders 8tand 8tthe
8tpublic 8ta 8tstandard, 8tcomprehensive, 8tup-to-date 8tlook 8tup 8tand 8tdownloadable 8tresource
8tabout 8tmedicines?
a. American 8tDrug 8tIndex
b. American 8tHospital 8tFormulary
c. DailyMed
d. Drug 8tReference
ANS: 8t C
DailyMed 8tmakes 8tavailable 8tto 8thealthcare 8tproviders 8tand 8tthe 8tpublic 8ta 8tstandard,
8tcomprehensive,8tup-to-date 8tlook 8tup 8tand 8tdownloadable 8tresource 8tabout 8tmedicines. 8tThe
8tAmerican 8tDrug 8tIndex 8tis8tnot 8tappropriate 8tfor 8tpatient 8tuse. 8tThe 8tAmerican 8tHospital
8tFormulary 8tis 8tnot 8tappropriate 8tfor 8tpatient 8t use. 8t The 8tdrug 8treference 8t is 8t not 8t appropriate
8t for 8tpatient 8t use.
DIF: Cognitive 8tLevel: 8tKnowledge REF: 8 t p. 8t3 8t| 8tp. 8t4 OBJ:
8t38tNAT: 8 t NCLEX 8tClient 8t Needs 8t Category: 8tPhysiological 8tIntegrity
TOP: 8 t Nursing 8tProcess 8tStep: 8tImplementation
CON: 8 t Safety 8t| 8tPatient 8tEducation 8t| 8tClinical 8tJudgment
6. Which 8tlegislation 8tauthorizes 8tthe 8tFDA 8tto 8tdetermine 8tthe 8tsafety8tof 8ta 8tdrug 8tbefore 8tits 8tmarketing?
a. Federal 8tFood, 8tDrug, 8tand 8tCosmetic 8tAct 8t(1938)
b. Durham 8tHumphrey 8tAmendment 8t (1952)
, Test 8tBank 8tFor 8tClayton’s 8tBasic 8tPharmacology 8tfor 8tNurses 8t19th 4
8tEdition
c. Controlled 8tSubstances 8tAct 8t(1970)
d. Kefauver 8tHarris 8tDrug 8tAmendment 8t(1962)
ANS: 8 t A
The 8tFederal 8tFood, 8tDrug, 8tand 8tCosmetic 8tAct 8tof 8t1938 8tauthorized 8tthe 8tFDA 8tto
8tdetermine 8tthe 8tsafety 8tof 8tall 8tdrugs 8tbefore 8tmarketing. 8tLater 8tamendments 8tand 8tacts
8thelped 8ttighten 8tFDA 8tcontrol 8tand 8tensure 8tdrug 8tsafety. 8tThe 8tDurham 8tHumphrey
8tAmendment 8tdefines 8tthe 8tkinds 8tof 8tdrugs 8tthat 8tcannot 8tbe 8tused 8tsafely 8twithout 8tmedical
8tsupervision 8tand 8trestricts 8ttheir 8tsale 8tto 8tprescription 8tby 8ta 8tlicensed 8tpractitioner. 8tThe
8tControlled 8tSubstances 8tAct 8taddresses 8tonly 8tcontrolled 8tsubstances 8tand8ttheir 8tcategorization.
8tThe 8tKefauver 8tHarris 8tDrug 8tAmendment 8t ensures 8tdrug 8tefficacy 8tand 8tgreater8tdrug 8tsafety.
8tDrug 8tmanufacturers 8tare 8trequired 8tto 8tprove 8tto 8tthe 8tFDA 8tthe 8teffectiveness 8tof 8ttheir
8tproducts 8tbefore 8tmarketing 8tthem.
DIF: Cognitive 8tLevel: 8tKnowledge REF: 8tp. 8t 5 8tTable 8tl.3
OBJ: 8 t 5 NAT: 8tNCLEX 8tClient 8tNeeds 8tCategory: 8tPhysiological
8tIntegrity8tTOP: 8 t Nursing 8tProcess 8t Step: 8tAssessment
CON: 8 t Safety 8t| 8tPatient 8t Education 8t| 8tEvidence 8t| 8tHealth 8tCare 8tLaw
7. Which 8tclassification 8tdoes 8tmeperidine 8t(Demerol) 8tfall 8tunder?
a. I
b. II
c. III
d. IV
ANS: 8 t B
Meperidine 8t(Demerol) 8tis 8ta 8tSchedule 8tII 8tdrug; 8tit 8thas 8ta 8thigh 8tpotential 8tfor 8tabuse 8tand
8tmay 8tlead 8tto8s
t evere 8tpsychological 8tand 8tphysical 8tdependence. 8tSchedule 8tI 8tdrugs 8thave 8thigh
8tpotential 8tfor 8tabuse8a
t nd 8tno 8trecognized 8tmedical 8tuse. 8tSchedule 8tIII 8tdrugs 8thave 8tsome
8tpotential 8tfor 8tabuse. 8tUse 8tmay 8tlead 8tto 8tlow 8tto 8tmoderate 8tphysical 8tdependence 8tor 8thigh
8tpsychological 8tdependence. 8tSchedule 8tIV8tdrugs 8thave 8tlow 8tpotential 8tfor 8tabuse. 8tUse 8tmay
8tlead 8tto 8tlimited 8tphysical 8tor 8tpsychological 8tdependence.
DIF: Cognitive 8tLevel: 8tKnowledge REF: 8 t p. 8t10 OBJ:
8t28tNAT: 8 t NCLEX 8tClient 8tNeeds 8tCategory: 8tSafe, 8tEffective 8tCare
8tEnvironment
TOP: 8 t Nursing 8tProcess 8tStep: 8tAssessment CON: 8 t Patient 8tEducation 8t| 8tAddiction 8t| 8tPain
8. Which 8taction 8twould 8tthe 8tFDA 8ttake 8tto 8texpedite 8tdrug 8tdevelopment 8t and 8tapproval 8tfor 8tan
outbreak8tof 8tsmallpox?
8t
a. List 8tsmallpox 8tas 8ta 8thealth 8torphan 8tdisease.
b. Omit 8tthe 8tpreclinical 8tresearch 8tphase.
c. Extend 8tthe 8tclinical 8tresearch 8tphase.
d. Fast 8ttrack 8tthe 8tinvestigational 8tdrug.
ANS: 8t D
Once 8tthe 8tInvestigational 8tNew 8tDrug 8tApplication 8thas 8tbeen 8tapproved, 8tthe 8tdrug 8tcan
8treceive 8thighest 8tpriority 8twithin 8tthe 8tagency, 8twhich 8tis 8tcalled 8tfast 8ttracking. 8tA 8tsmallpox
8toutbreak 8twould 8tbecome 8ta 8tpriority 8tconcern 8tin 8tthe 8tworld. 8tOrphan 8tdiseases 8tare 8tnot
8tresearched 8tin 8ta 8tpriority 8tmanner. 8tPreclinical 8tresearch 8tis 8tnot 8tomitted. 8tExtending 8tany
8tphase 8tof 8tthe 8tresearch 8twould 8tmean8ta 8tlonger 8ttime 8tto 8tdevelop 8ta 8tvaccine. 8tThe 8tFDA 8tmust
8tensure 8tthat 8tall 8tphases 8tof 8tthe 8tpreclinical 8tand8tclinical 8tresearch 8tphase 8t have 8t been
8tcompleted 8t in 8ta 8t safe 8tmanner.
DIF: Cognitive 8tLevel: 8tKnowledge REF: 8t 8t 8tp. 8t7 OBJ: 8 t 5
NURSES 19TH EDITIONBY MICHELLE J. WILLIHNGANZ,
SAMUEL L. GUREVITZ, BRUCE CLAYTON COMPLETE
,Chapter 8t01: 8tDrug 8tDefinitions, 8tStandards, 8tand 8tInformation 8tSources
8tWillihnganz: 8tClayton’s 8tBasic 8tPharmacology 8t for 8tNurses, 8t19th 8tEdition
MULTIPLE
8tCHOICE
1. Which 8tname 8tidentifies 8ta 8tdrug 8tlisted 8tby 8tthe 8tUS
8t Food 8tand8tDrug 8tAdministration 8t(FDA)?
a. Brand
b. Nonproprietary
c. Official
d. Trademark
ANS: 8t C
The 8tofficial 8tname 8tis 8tthe 8 t name 8tunder 8twhich 8ta 8tdrug 8tis
8tlisted 8tby 8tthe 8tFDA. 8tThe 8tbrand 8tname, 8tor 8ttrademark, 8tis
8tthe 8tname 8tgiven 8tto 8ta 8tdrug 8tby 8tits 8tmanufacturer. 8tThe
8tnonproprietary, 8tor 8tgeneric, 8tname 8tis 8tprovided 8tby 8tthe
8tUnited 8tStates 8tAdopted 8tNames 8tCouncil.
DIF: Cognitive 8tLevel: 8tKnowledge REF: 8 t p. 8t9
OBJ: 8t1NAT: 8tNCLEX 8tClient 8tNeeds 8tCategory: 8tSafe,
8tEffective 8tCare8E
t nvironment 8tTOP: 8 t Nursing 8tProcess 8tStep:
8tAssessment CON:
8tPatient 8tEducation
2. Which 8tsource 8tcontains 8tinformation 8tspecific 8tto 8tnutritional 8tsupplements?
a. USP 8tDictionary 8tof 8tUSAN 8t &8tInternational 8tDrug 8tNames
b. Natural 8tMedicines 8tComprehensive 8tDatabase
c. United 8tStates 8tPharmacopoeia/National 8tFormulary 8t(USP 8tNF)
d. Drug 8tInteraction 8tFacts
ANS: 8t C
United 8tStates 8tPharmacopoeia/National 8tFormulary 8tcontains 8tinformation 8tspecific 8tto
8tnutritional8s t upplements. 8tUSP 8tDictionary 8tof 8tUSAN 8t& 8tInternational 8tDrug 8tNames 8tis 8ta
8tcompilation 8tof 8tdrug8tnames, 8tpronunciation 8tguide, 8tand 8tpossible 8tfuture 8tFDA 8tapproved
8tdrugs; 8tit 8tdoes 8tnot 8tinclude 8tnutritional 8tsupplements. 8t Natural 8tMedicines 8tComprehensive
8tDatabase 8tcontains
evidence-based 8tinformation 8ton 8therbal 8tmedicines 8tand 8therbal 8tcombination 8tproducts; 8tit
8tdoes 8tnot8tinclude 8tinformation 8tspecific 8tto 8tnutritional 8tsupplements. 8tDrug 8tInteraction
8tFacts 8tcontains 8tcomprehensive 8t information 8ton 8tdrug 8t interaction 8tfacts; 8tit 8t does 8tnot
8t include 8tnutritional 8tsupplements.
DIF: Cognitive 8tLevel: 8tKnowledge REF: 8 t p. 8t4 OBJ:
8t38tNAT: 8 t NCLEX 8tClient 8t Needs 8t Category: 8tPhysiological 8tIntegrity
TOP: 8 t Nursing 8tProcess 8tStep: 8tAssessment CON: 8 t Nutrition 8t| 8tPatient 8t Education
3. Which 8tdrug 8treference 8tcontains 8tdrug 8tmonographs 8tthat 8tdescribe 8tall 8tdrugs 8tin 8ta 8ttherapeutic 8tclass?
a. Drug 8tFacts 8tand 8tComparisons
,Test 8tBank 8tFor 8tClayton’s 8tBasic 8tPharmacology 8tfor 8tNurses 8t19th 3
8tEdition
b. Drug 8tInteraction 8tFacts
c. Handbook 8ton 8tInjectable 8tDrugs
d. Martindale—The 8tComplete 8tDrug 8tReference
ANS: 8 t A
Drug 8tFacts 8tand 8tComparisons 8tcontains 8tdrug 8tmonographs 8tthat 8tdescribe 8tall
8tdrugs 8tin 8ta8ttherapeutic 8tclass. 8tMonographs 8tare 8tformatted 8tas 8ttables 8tto 8tallow
8tcomparison 8tof 8tsimilar8tproducts, 8tbrand 8tnames, 8tmanufacturers, 8tcost 8tindices, 8tand
8tavailable 8tdosage 8tforms 8tOnline 8tversion 8tis 8tavailable.
DIF: Cognitive 8tLevel: 8tKnowledge REF: 8 t p. 8t4 8tTable 8t1.2
OBJ: 8t 8t 8 t 3 NAT: 8 t NCLEX 8tClient 8tNeeds 8tCategory: 8tPhysiological 8tIntegrity
TOP: 8 t Nursing 8tProcess 8tStep: 8tAssessment CON: 8 t Safety 8t| 8tPatient 8tEducation 8t| 8tClinical 8tJudgment
4. Which 8tdrug 8treference 8tcontains 8t monographs 8tabout 8t virtually 8tevery8tsingle-entity8tdrug
available8tin 8tthe 8tUnited 8tStates 8tand 8tdescribes 8ttherapeutic 8tuses 8tof 8tdrugs, 8tincluding
8t
approved 8tand 8tunapproved 8tuses?
8t
a. Martindale: 8tThe 8tComplete 8tDrug 8tReference
b. AHFS 8tDrug 8tInformation
c. Drug 8tReference
d. Drug 8tFacts 8tand 8tComparisons
ANS: 8 t B
AHFS 8tDrug 8tInformation 8tcontains 8tmonographs 8tabout 8tvirtually 8tevery 8tsingle-entity 8tdrug
8tavailable 8tin 8tthe 8tUnited 8tStates 8tand 8tdescribes 8ttherapeutic 8tuses 8tof 8tdrugs, 8t including
8tapproved 8tand8tunapproved 8t uses.
DIF: Cognitive 8tLevel: 8tKnowledge REF: 8 t p. 8t4 8tTable 8t1.2
OBJ: 8t 8t 8 t 3 NAT: 8 t NCLEX 8tClient 8tNeeds 8tCategory: 8tPhysiological 8tIntegrity
TOP: 8 t Nursing 8tProcess 8tStep: 8tPlanning CON: 8 t Safety 8t| 8tPatient 8tEducation 8t| 8tClinical 8tJudgment
5. Which 8tonline 8tdrug 8treference 8tmakes 8tavailable 8tto 8thealthcare 8tproviders 8tand 8tthe
8tpublic 8ta 8tstandard, 8tcomprehensive, 8tup-to-date 8tlook 8tup 8tand 8tdownloadable 8tresource
8tabout 8tmedicines?
a. American 8tDrug 8tIndex
b. American 8tHospital 8tFormulary
c. DailyMed
d. Drug 8tReference
ANS: 8t C
DailyMed 8tmakes 8tavailable 8tto 8thealthcare 8tproviders 8tand 8tthe 8tpublic 8ta 8tstandard,
8tcomprehensive,8tup-to-date 8tlook 8tup 8tand 8tdownloadable 8tresource 8tabout 8tmedicines. 8tThe
8tAmerican 8tDrug 8tIndex 8tis8tnot 8tappropriate 8tfor 8tpatient 8tuse. 8tThe 8tAmerican 8tHospital
8tFormulary 8tis 8tnot 8tappropriate 8tfor 8tpatient 8t use. 8t The 8tdrug 8treference 8t is 8t not 8t appropriate
8t for 8tpatient 8t use.
DIF: Cognitive 8tLevel: 8tKnowledge REF: 8 t p. 8t3 8t| 8tp. 8t4 OBJ:
8t38tNAT: 8 t NCLEX 8tClient 8t Needs 8t Category: 8tPhysiological 8tIntegrity
TOP: 8 t Nursing 8tProcess 8tStep: 8tImplementation
CON: 8 t Safety 8t| 8tPatient 8tEducation 8t| 8tClinical 8tJudgment
6. Which 8tlegislation 8tauthorizes 8tthe 8tFDA 8tto 8tdetermine 8tthe 8tsafety8tof 8ta 8tdrug 8tbefore 8tits 8tmarketing?
a. Federal 8tFood, 8tDrug, 8tand 8tCosmetic 8tAct 8t(1938)
b. Durham 8tHumphrey 8tAmendment 8t (1952)
, Test 8tBank 8tFor 8tClayton’s 8tBasic 8tPharmacology 8tfor 8tNurses 8t19th 4
8tEdition
c. Controlled 8tSubstances 8tAct 8t(1970)
d. Kefauver 8tHarris 8tDrug 8tAmendment 8t(1962)
ANS: 8 t A
The 8tFederal 8tFood, 8tDrug, 8tand 8tCosmetic 8tAct 8tof 8t1938 8tauthorized 8tthe 8tFDA 8tto
8tdetermine 8tthe 8tsafety 8tof 8tall 8tdrugs 8tbefore 8tmarketing. 8tLater 8tamendments 8tand 8tacts
8thelped 8ttighten 8tFDA 8tcontrol 8tand 8tensure 8tdrug 8tsafety. 8tThe 8tDurham 8tHumphrey
8tAmendment 8tdefines 8tthe 8tkinds 8tof 8tdrugs 8tthat 8tcannot 8tbe 8tused 8tsafely 8twithout 8tmedical
8tsupervision 8tand 8trestricts 8ttheir 8tsale 8tto 8tprescription 8tby 8ta 8tlicensed 8tpractitioner. 8tThe
8tControlled 8tSubstances 8tAct 8taddresses 8tonly 8tcontrolled 8tsubstances 8tand8ttheir 8tcategorization.
8tThe 8tKefauver 8tHarris 8tDrug 8tAmendment 8t ensures 8tdrug 8tefficacy 8tand 8tgreater8tdrug 8tsafety.
8tDrug 8tmanufacturers 8tare 8trequired 8tto 8tprove 8tto 8tthe 8tFDA 8tthe 8teffectiveness 8tof 8ttheir
8tproducts 8tbefore 8tmarketing 8tthem.
DIF: Cognitive 8tLevel: 8tKnowledge REF: 8tp. 8t 5 8tTable 8tl.3
OBJ: 8 t 5 NAT: 8tNCLEX 8tClient 8tNeeds 8tCategory: 8tPhysiological
8tIntegrity8tTOP: 8 t Nursing 8tProcess 8t Step: 8tAssessment
CON: 8 t Safety 8t| 8tPatient 8t Education 8t| 8tEvidence 8t| 8tHealth 8tCare 8tLaw
7. Which 8tclassification 8tdoes 8tmeperidine 8t(Demerol) 8tfall 8tunder?
a. I
b. II
c. III
d. IV
ANS: 8 t B
Meperidine 8t(Demerol) 8tis 8ta 8tSchedule 8tII 8tdrug; 8tit 8thas 8ta 8thigh 8tpotential 8tfor 8tabuse 8tand
8tmay 8tlead 8tto8s
t evere 8tpsychological 8tand 8tphysical 8tdependence. 8tSchedule 8tI 8tdrugs 8thave 8thigh
8tpotential 8tfor 8tabuse8a
t nd 8tno 8trecognized 8tmedical 8tuse. 8tSchedule 8tIII 8tdrugs 8thave 8tsome
8tpotential 8tfor 8tabuse. 8tUse 8tmay 8tlead 8tto 8tlow 8tto 8tmoderate 8tphysical 8tdependence 8tor 8thigh
8tpsychological 8tdependence. 8tSchedule 8tIV8tdrugs 8thave 8tlow 8tpotential 8tfor 8tabuse. 8tUse 8tmay
8tlead 8tto 8tlimited 8tphysical 8tor 8tpsychological 8tdependence.
DIF: Cognitive 8tLevel: 8tKnowledge REF: 8 t p. 8t10 OBJ:
8t28tNAT: 8 t NCLEX 8tClient 8tNeeds 8tCategory: 8tSafe, 8tEffective 8tCare
8tEnvironment
TOP: 8 t Nursing 8tProcess 8tStep: 8tAssessment CON: 8 t Patient 8tEducation 8t| 8tAddiction 8t| 8tPain
8. Which 8taction 8twould 8tthe 8tFDA 8ttake 8tto 8texpedite 8tdrug 8tdevelopment 8t and 8tapproval 8tfor 8tan
outbreak8tof 8tsmallpox?
8t
a. List 8tsmallpox 8tas 8ta 8thealth 8torphan 8tdisease.
b. Omit 8tthe 8tpreclinical 8tresearch 8tphase.
c. Extend 8tthe 8tclinical 8tresearch 8tphase.
d. Fast 8ttrack 8tthe 8tinvestigational 8tdrug.
ANS: 8t D
Once 8tthe 8tInvestigational 8tNew 8tDrug 8tApplication 8thas 8tbeen 8tapproved, 8tthe 8tdrug 8tcan
8treceive 8thighest 8tpriority 8twithin 8tthe 8tagency, 8twhich 8tis 8tcalled 8tfast 8ttracking. 8tA 8tsmallpox
8toutbreak 8twould 8tbecome 8ta 8tpriority 8tconcern 8tin 8tthe 8tworld. 8tOrphan 8tdiseases 8tare 8tnot
8tresearched 8tin 8ta 8tpriority 8tmanner. 8tPreclinical 8tresearch 8tis 8tnot 8tomitted. 8tExtending 8tany
8tphase 8tof 8tthe 8tresearch 8twould 8tmean8ta 8tlonger 8ttime 8tto 8tdevelop 8ta 8tvaccine. 8tThe 8tFDA 8tmust
8tensure 8tthat 8tall 8tphases 8tof 8tthe 8tpreclinical 8tand8tclinical 8tresearch 8tphase 8t have 8t been
8tcompleted 8t in 8ta 8t safe 8tmanner.
DIF: Cognitive 8tLevel: 8tKnowledge REF: 8t 8t 8tp. 8t7 OBJ: 8 t 5
